Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Pharmacokinetics of TS-161 in Healthy Volunteers
NCT03919409Phase 1Completed
- Sponsor
- Taisho Pharmaceutical
- Start
- Jun 2019
- Primary completion
- Feb 2020
- Modality
- Prodrugs/Conditional Activator Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of TP0473292 in major depressive disorder (MDD) (9 cohorts), sponsored by Taisho Pharmaceutical. Primary endpoints: Incidence and severity of Adverse Events, TS-161 Plasma Pharmacokinetic Profile - Cmax at Day 10 and 9 more. Started Jun 2019; status: completed.
02
Drugs
TP0473292
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on NCT03919409.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03919409.